Amour Venter

5.1k total citations
43 papers, 2.8k citations indexed

About

Amour Venter is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Amour Venter has authored 43 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Infectious Diseases, 32 papers in Epidemiology and 10 papers in Surgery. Recurrent topics in Amour Venter's work include Tuberculosis Research and Epidemiology (34 papers), Mycobacterium research and diagnosis (22 papers) and Pneumonia and Respiratory Infections (12 papers). Amour Venter is often cited by papers focused on Tuberculosis Research and Epidemiology (34 papers), Mycobacterium research and diagnosis (22 papers) and Pneumonia and Respiratory Infections (12 papers). Amour Venter collaborates with scholars based in South Africa, United States and Switzerland. Amour Venter's co-authors include Andreas H. Diacon, Peter R. Donald, Rodney Dawson, Christo van Niekerk, Florian von Groote-Bidlingmaier, J. S. Maritz, Paul D. van Helden, Melvin Spigelman, Carl M. Mendel and Daniel E. Everitt and has published in prestigious journals such as The Lancet, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Amour Venter

42 papers receiving 2.7k citations

Peers

Countries citing papers authored by Amour Venter

Since Specialization

Citations

This map shows the geographic impact of Amour Venter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amour Venter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amour Venter more than expected).

Fields of papers citing papers by Amour Venter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amour Venter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amour Venter. The network helps show where Amour Venter may publish in the future.

Co-authorship network of co-authors of Amour Venter

This figure shows the co-authorship network connecting the top 25 collaborators of Amour Venter. A scholar is included among the top collaborators of Amour Venter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amour Venter. Amour Venter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Liquid mycobacterial culture outcomes after different sputum collection techniques before and during treatment 2019 ·Tuberculosis ·(unknown), (unknown), (unknown), Sven O. Friedrich, Neil Martinson, Amour Venter, Lize van der Merwe, Andreas H. Diacon	3
2	A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing 2016 ·Journal of Clinical Microbiology ·Koné Kaniga, Daniela María Cirillo, Sven Hoffner, Nazir Ismail, Davinder Kaur, Nacer Lounis, Beverly Metchock, Gaby E. Pfyffer, Amour Venter	35
3	A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis 2015 ·American Journal of Respiratory and Critical Care Medicine ·Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Kim Narunsky, Jeannine du Bois, Amour Venter, Patrick Phillips, Stephen H. Gillespie, Timothy D. McHugh, Michael Höelscher, Norbert Heinrich, Sunita Rehal, Dick van Soolingen, Jakko van Ingen, Cécile Magis-Escurra, David M. Burger, Georgette Plemper van Balen, Rob E. Aarnoutse	213
4	Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline 2015 ·American Journal of Respiratory and Critical Care Medicine ·Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, Gregory Symons, Amour Venter, Peter R. Donald, Christo van Niekerk, Daniel E. Everitt, (unknown), Divan A. Burger, Robert Schall, Carl M. Mendel	165
5	Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis 2015 ·The Lancet ·Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, Christo van Niekerk, Peter R. Donald, Divan A. Burger, Robert Schall, Melvin Spigelman, Almari Conradie, Kathleen D. Eisenach, Amour Venter, Prudence Ive, Liesl Page‐Shipp, Ebrahim Variava, Klaus Reither, Nyanda Elias Ntinginya, Alexander S. Pym, Florian von Groote-Bidlingmaier, Carl M. Mendel	184
6	Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens 2013 ·Tuberculosis ·Andreas H. Diacon, Lize van der Merwe, Anne‐Marie Demers, Florian von Groote-Bidlingmaier, Amour Venter, Peter R. Donald	31
7	Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment 2013 ·The Lancet Respiratory Medicine ·Sven O. Friedrich, Andrea Rachow, Elmar Saathoff, Kasha P. Singh, Chacha Mangu, Rodney Dawson, Patrick Phillips, Amour Venter, Matthew Bates, Catharina Boehme, Norbert Heinrich, Robert D. Hunt, Martin J. Boeree, Alimuddin Zumla, Timothy D. McHugh, Stephen H. Gillespie, Andreas H. Diacon, Michael Höelscher	128
8	14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial 2012 ·The Lancet ·Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, Gregory Symons, Amour Venter, Peter R. Donald, Christo van Niekerk, Daniel E. Everitt, Helen Winter, Piet Becker, Carl M. Mendel, Melvin Spigelman	328
9	Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents 2011 ·Clinical Microbiology and Infection ·Andreas H. Diacon, J. S. Maritz, Amour Venter, Paul D. van Helden, Rodney Dawson, Peter R. Donald	52
10	Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients 2011 ·The International Journal of Tuberculosis and Lung Disease ·Andreas H. Diacon, Rodney Dawson, M. Hanekom, Kim Narunsky, Amour Venter, Norbert Hittel, Lawrence Geiter, Charles D. Wells, Anne Paccaly, Peter R. Donald	157
11	Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents 2010 ·European Journal of Clinical Microbiology & Infectious Diseases ·Andreas H. Diacon, J. S. Maritz, Amour Venter, Paul D. van Helden, Koen Andries, D. F. McNeeley, Peter R. Donald	58
12	Seabird predation by white shark, Carcharodon carcharias, and Cape fur seal, Arctocephalus pusillus pusillus, at Dyer Island : research article 2006 ·African Journal of Wildlife Research ·Ryan Johnson, Amour Venter, M.N. Bester, (unknown)	14
13	The non-payment of mortgage bonds in South Africa : the voice of defaulters : research article 2005 ·Acta Structilia ·(unknown), Lucius Botes, (unknown), Amour Venter	1
14	Monitoring the ingestion of anti-tuberculosis drugs by simple non-invasive methods 2005 ·International Journal of Pharmaceutics ·F A Sirgel, (unknown), Amour Venter, Grant Langdon, Philip Smith, P. R. Donald	4
15	The Influence of Human N-Acetyltransferase Genotype on the Early Bactericidal Activity of Isoniazid 2004 ·Clinical Infectious Diseases ·Peter R. Donald, F A Sirgel, Amour Venter, D. P. Parkin, H. I. Seifart, B. W. Van de Wal, Cedric J. Werely, Paul D. van Helden, J. S. Maritz	69
16	Early bactericidal activity of antituberculosis agents 2003 ·Expert Review of Anti-infective Therapy ·Peter R. Donald, F A Sirgel, Amour Venter, D. P. Parkin, H. I. Seifart, B. W. Van de Wal, J. S. Maritz, P. Bernard Fourie	51
17	Diel fluctuations of phosphatase and nitrate reductase activities in vitro and in situ in the Vaal River (South Africa) 2002 ·SIL Proceedings 1922-2010 ·(unknown), (unknown), Amour Venter, A. J. H. Pieterse	1
18	The early bactericidal activity of amikacin in pulmonary tuberculosis. 2001 ·PubMed ·Peter R. Donald, Frederick A. Sirgel, Amour Venter, E.M.E. Smit, D. P. Parkin, B. W. Van de Wal, D.A. Mitchison	27
19	Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis 1997 ·Journal of Medical Microbiology ·T. C. Victor, Robin M. Warren, (unknown), A. Jordaan, (unknown), Amour Venter, F A Sirgel, H. Simon Schaaf, Peter R. Donald, M. Richardson, Michael H. Cynamon, Paul D. van Helden	36
20	B-Ether derivatives of categchlomaines. The role of the B-hydroxyl group in interactions between drug and B-receptor 1988 ·South African Journal of Science ·Amour Venter, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact